Пређи на садржај

Болест српастих ћелија (педијатрија)

Превенција кризе

Фармаколошка индукција феталног хемоглобина

Pharmacotherapy in sickle cell disease—state of the art and future prospects. (отвара нови прозор)

Hankins J, Aygun B.

Извор‎: Br J Haematol 2009;145(3):296-308.

Индекс‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (отвара нови прозор)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (отвара нови прозор)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Извор‎: Blood 2005;106(7):2269-75.

Индекс‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (отвара нови прозор)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (отвара нови прозор)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Извор‎: N Engl J Med 2020;382(26):2524-33.

Индекс‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (отвара нови прозор)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (отвара нови прозор)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Извор‎: Br J Haematol 2013;161(6):852-60.

Индекс‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (отвара нови прозор)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (отвара нови прозор)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Извор‎: Arch Dis Child 2013;98(11):908-14.

Индекс‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (отвара нови прозор)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (отвара нови прозор)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Извор‎: Pediatrics 2008;122(6):1332-42.

Индекс‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (отвара нови прозор)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (отвара нови прозор)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Извор‎: Blood 2012;120(22):4304-10.

Индекс‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (отвара нови прозор)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (отвара нови прозор)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Извор‎: N Engl J Med 2019;380(2):121-31.

Индекс‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (отвара нови прозор)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (отвара нови прозор)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Извор‎: J Pediatr 2002;140(2):225-9.

Индекс‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (отвара нови прозор)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (отвара нови прозор)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Извор‎: Pediatrics 2013;132(4):677-83.

Индекс‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (отвара нови прозор)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (отвара нови прозор)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Извор‎: Lancet 2011;377(9778):1663-72.

Индекс‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (отвара нови прозор)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (отвара нови прозор)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Извор‎: Lancet 2016;387(10019):661-70.

Индекс‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (отвара нови прозор)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (отвара нови прозор)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Извор‎: Blood 2004;103(6):2039-45.

Индекс‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (отвара нови прозор)

Превенција инфекција и других компликација

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (отвара нови прозор)

Hirst C, Owusu-Ofori S.

Извор‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Индекс‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (отвара нови прозор)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (отвара нови прозор)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Извор‎: Lancet Haematol 2021;8(5):e323-33.

Индекс‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (отвара нови прозор)

Sickle cell disease. (отвара нови прозор)

Meremikwu MM, Okomo U.

Извор‎: BMJ Clin Evid 2011;02:2402.

Индекс‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (отвара нови прозор)

A phase 3 trial of l-glutamine in sickle cell disease. (отвара нови прозор)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Извор‎: N Engl J Med 2018;379(3):226-35.

Индекс‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (отвара нови прозор)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (отвара нови прозор)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Извор‎: Blood. 2023 23;141(12):1402-10.

Индекс‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (отвара нови прозор)

Malaria chemoprophylaxis in sickle cell disease. (отвара нови прозор)

Oniyangi O, Omari AA.

Извор‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Индекс‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (отвара нови прозор)